{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cardiac+CT+Scan&page=7", "query": { "intervention": "Cardiac CT Scan", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 358, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cardiac+CT+Scan&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cardiac+CT+Scan&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T21:29:02.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06523166", "title": "Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Device Related Thrombosis", "Peri-device Leak" ], "interventions": [ { "name": "Transesophageal echocardiography (TEE)", "type": "PROCEDURE" }, { "name": "Cardiac CTA", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University Hospitals Cleveland Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2026-03-27", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 5, "location_summary": "Los Angeles, California • Roslyn, New York • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Roslyn", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06523166" }, { "nct_id": "NCT01313572", "title": "Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Apadenoson SPECT-MPI", "type": "DRUG" }, { "name": "Adenosine SPECT-MPI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2011-08", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-05-01", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313572" }, { "nct_id": "NCT00783302", "title": "Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Artery Disease (CAD)" ], "interventions": [], "intervention_types": [], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 885, "start_date": "2008-09", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2014-12-11", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00783302" }, { "nct_id": "NCT02769962", "title": "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Urothelial Cancer", "Lung Neoplasms", "Small Cell Lung Cancer", "Prostate Cancer" ], "interventions": [ { "name": "EP0057", "type": "DRUG" }, { "name": "olaparib", "type": "DRUG" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest, abdomen, and pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2016-05-09", "completion_date": "2025-03-04", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02769962" }, { "nct_id": "NCT02379988", "title": "Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Verify radiation dose to heart and lung", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2014-11-06", "completion_date": "2016-07-03", "has_results": true, "last_update_posted_date": "2023-05-17", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02379988" }, { "nct_id": "NCT05035407", "title": "T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kita-kyushu Lung Cancer Antigen 1, Human" ], "interventions": [ { "name": "IL-2 (Aldesleukin)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "KK-LC-1 TCR", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CXR", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2022-03-08", "completion_date": "2025-07-16", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05035407" }, { "nct_id": "NCT00780234", "title": "Pioglitazone for Lung Cancer Chemoprevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Endobronchial Dysplasia" ], "interventions": [ { "name": "fluorescence bronchoscopy", "type": "PROCEDURE" }, { "name": "quantitative high resolution CT scan", "type": "PROCEDURE" }, { "name": "PIOGLITAZONE VS. PLACEBO 30 mg", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2009-08", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2019-04-11", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 2, "location_summary": "Denver, Colorado • Nashville, Tennessee", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00780234" }, { "nct_id": "NCT06968195", "title": "Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma", "Recurrent Hepatocellular Carcinoma", "Refractory Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Anti-GPC3-CAR Autologous T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-11-15", "completion_date": "2029-05-30", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06968195" }, { "nct_id": "NCT00705458", "title": "Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease", "Angina Pectoris", "Unstable Angina", "Acute Coronary Syndrome" ], "interventions": [ { "name": "Coronary Computed Tomography Angiography", "type": "PROCEDURE" }, { "name": "Stress Nuclear Myocardial Perfusion Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 400, "start_date": "2008-07", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00705458" }, { "nct_id": "NCT04739800", "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Fallopian Tube Mucinous Adenocarcinoma", "Recurrent Fallopian Tube Transitional Cell Carcinoma", "Recurrent Fallopian Tube Undifferentiated Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Seromucinous Carcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Ovarian Undifferentiated Carcinoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Undifferentiated Carcinoma", "Refractory Fallopian Tube Clear Cell Adenocarcinoma", "Refractory Fallopian Tube Endometrioid Adenocarcinoma", "Refractory Fallopian Tube High Grade Serous Adenocarcinoma", "Refractory Fallopian Tube Mucinous Adenocarcinoma", "Refractory Fallopian Tube Transitional Cell Carcinoma", "Refractory Fallopian Tube Undifferentiated Carcinoma", "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian Endometrioid Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Refractory Ovarian Low Grade Serous Adenocarcinoma", "Refractory Ovarian Mucinous Adenocarcinoma", "Refractory Ovarian Seromucinous Carcinoma", "Refractory Ovarian Transitional Cell Carcinoma", "Refractory Ovarian Undifferentiated Carcinoma", "Refractory Primary Peritoneal Clear Cell Adenocarcinoma", "Refractory Primary Peritoneal Endometrioid Adenocarcinoma", "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Transitional Cell Carcinoma", "Refractory Primary Peritoneal Undifferentiated Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2021-06-10", "completion_date": "2027-06-25", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-30T21:29:02.508Z", "location_count": 384, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 288 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04739800" } ] }